NASDAQ:XERS

Xeris Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy XERS

*Your capital is at risk

$5.89

-0.110 (-1.83%)

At Close: Jun 03, 2026

Xeris Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -36.34. In total, the insiders bought 4.12M and sold 1.83M XERS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-36.34
● Buy	4.12M shares
● Sell	1.83M shares
52% Buy Activity Moderate Negative Correlation
Buy Signal Low Confidence Jan 30, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -36.34. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 01, 2026 Sell	Common Stock S-Sale	Hecht Beth See Remarks	Officer	16 667 Value: $101.0K
May 01, 2026 Sell	Common Stock S-Sale	Hecht Beth See Remarks	Officer	16 667 Value: $103.8K
Apr 01, 2026 Sell	Common Stock S-Sale	Hecht Beth See Remarks	Officer	16 667 Value: $99.9K
Mar 30, 2026 Sell	Common Stock S-Sale	Brady James Aloysius Director	Director	10 834 Value: $60.0K
Mar 12, 2026 Buy	Common Stock M-Exempt	Mcculloch Kevin See Remarks	Officer	4 Value: $16
Mar 12, 2026 Buy	Common Stock M-Exempt	Mcculloch Kevin See Remarks	Officer	48 894 Value: $200.0K
Mar 12, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Mcculloch Kevin See Remarks	Officer	4 Value: $16
Mar 12, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Mcculloch Kevin See Remarks	Officer	48 894 Value: $200.0K
Mar 05, 2026 Buy	Common Stock M-Exempt	Pieper Steven See Remarks	Officer	14 036 Value: $83.2K
Mar 05, 2026 Buy	Common Stock M-Exempt	Pieper Steven See Remarks	Officer	27 891 Value: $114.1K
Mar 05, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Pieper Steven See Remarks	Officer	14 036 Value: $83.2K
Mar 05, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Pieper Steven See Remarks	Officer	27 891 Value: $114.1K
Mar 02, 2026 Sell	Common Stock S-Sale	Hecht Beth See Remarks	Officer	16 567 Value: $103.4K
Mar 02, 2026 Sell	Common Stock S-Sale	Hecht Beth See Remarks	Officer	100 Value: $706
Feb 24, 2026 Sell	Common Stock F-InKind	Nguyen Anh Tu See Remarks	Officer	29 300 Value: $201.6K
Feb 02, 2026 Sell	Common Stock S-Sale	Hecht Beth See Remarks	Officer	16 667 Value: $124.1K
Jan 31, 2026 Sell	Common Stock F-InKind	Hecht Beth See Remarks	Officer	46 914 Value: $345.3K
Jan 31, 2026 Sell	Common Stock F-InKind	Pieper Steven See Remarks	Officer	27 319 Value: $201.1K
Jan 31, 2026 Sell	Common Stock F-InKind	Pieper Steven See Remarks	Officer	111 765 Value: $822.6K
Jan 31, 2026 Sell	Common Stock F-InKind	Mcculloch Kevin See Remarks	Officer	27 319 Value: $201.1K
Jan 31, 2026 Sell	Common Stock F-InKind	Mcculloch Kevin See Remarks	Officer	68 454 Value: $503.8K
Jan 31, 2026 Sell	Common Stock F-InKind	Shannon John Patrick Jr See Remarks	Officer	110 750 Value: $815.1K
Jan 31, 2026 Sell	Common Stock F-InKind	Shannon John Patrick Jr See Remarks	Officer	111 621 Value: $821.5K
Jan 31, 2026 Sell	Common Stock F-InKind	Shannon John Patrick Jr See Remarks	Officer	118 134 Value: $869.5K
Jan 31, 2026 Sell	Common Stock F-InKind	Mcculloch Kevin See Remarks	Officer	30 289 Value: $222.9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT XERIS PHARMACEUTICALS INC

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhi...

Read Full Profile Here